RBC Capital analyst Brian Abrahams maintained a Hold rating on Neurocrine (NBIX – Research Report) yesterday and set a price target of $148.00.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback